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Background: Symptoms of an adverse reaction to contrast agents for computed tomography are diverse ranging,
and sometimes serious. The goal of this study is to create a scoring rule to predict adverse reactions to contrast
agents used in computed tomography.
Methods: This was a retrospective cohort study of all adult patients undergoing contrast enhanced CT scan for
7 years. The subjects were randomly divided into either a derivation or validation group. Baseline data and clinically
relevant factors were collected from the electronic chart. Primary outcome was any acute adverse reactions to
contrast media, observed for during 24 hours after administration. All potential candidate predictors were included
in a forward stepwise logistic regression model. Prediction scores were assigned based on β coefficient. A receiver
operating characteristic (ROC) curve was drawn, and the area under the curve (AUC) and incidence of acute
adverse reactions at each point were obtained. The same process was performed in the validation group.
Results: 36,472 patients underwent enhanced CT imaging: 20,000 patients in the derivation group and 16,472 in the
validation group. A total of 409 (2.0%, 95% CI:1.9-2.3) and 347 (2.1%, 95% CI:1.9-2.3) acute adverse reactions were seen in
the derivation and validation groups. Logistic regression analysis revealed that prior adverse reaction to contrast agents,
urticaria, an allergic history to drugs other than contrast agents, contrast agent concentration >70%, age <50 years,
and total contrast agent dose >65 g were significant predictors of an acute adverse reaction. AUC was 0.70
(95% CI:0.67-0.73) and 0.67 (95% CI:0.64-0.70) in the derivation and validation groups.
Conclusions: We suggest a prediction model consisting of six predictors for acute adverse reactions to contrast agents
used in CT.Background
Computed tomography (CT) imaging has rapidly be-
come a commonplace diagnostic tool due to its utility in
a wide range of diseases. A national survey in the United
States estimates that approximately 70 million CT scan
are performed per year [1]. In Japan, the number of CT
scans performed is not only substantially higher than in
other countries, but continues to increase [2,3]. Previous
study reported the number of CT scans performed was
about 36,550,000 times a year [4]. As the number of CT
scanners increases, the number of diagnostic CT im-
aging studies increases as well as their side effects, in-
cluding iatrogenic cancer [5] and adverse events from
iodine-containing contrast agents [6,7].* Correspondence: daikoba@luke.or.jp
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reproduction in any medium, provided the orPrevious studies have shown that the incidence of
acute adverse reactions to contrast agents is approxi-
mately 2-3% with low-osmolarity contrast agents
(LOCAs) [8,9]. Symptoms of an adverse reaction to con-
trast agents are diverse ranging from flushing, pruritus,
uriticaria, and angioedema [10], with more severe side
effects including hypotension, loss of consciousness, to
potentially life-threatening bronchospasm and airway
obstruction [11]. These adverse events are hypersensitiv-
ity reaction, and classified into allergic reactions and
non-allergic reactions [12], the former, dependent on
[13], and the latter, independent on dose and infusion
rate [14]. In this study, we focused on all kinds of ad-
verse events for contrast agent for CT scans.
Risk factors for these adverse effects have been reported
in previous literature, with a history of immediate adverse
reaction to contrast agents being the most significant [15].
A history of allergy-mediated disease, including asthma,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cant risk factor [16]. However, no prior study has exam-
ined to quantitatively adverse effects of contrast agents. A
prediction rule may facilitate the pre- and post-imaging
management of patients requiring contrast enhanced CT
imaging. For instance, physicians can consider whether
they prescribe pre-medications for high risk patients based
on the rule. In other examples, physicians may choose per-
forming CT scans without contrast agent. Finally, physi-
cians can evaluate which patients they should observe
carefully and for a long time after CT scans. The goal of
this study is to evaluate risk factors for the incidence of
adverse reactions to contrast agents based on relevant pa-
tient demographic and clinical factors.
Methods
A retrospective cohort study of all adult patients who
underwent contrast enhanced CT imaging with intraven-
ous contrast agents from April 2004 through March 2011
was conducted at St. Luke's International Hospital, a large
community hospital in Tokyo, Japan. All potential prog-
nostic prediction parameters were collected prior to im-
aging and were based on previous studies, as well as
physician-driven clinical relevance. Parameters were com-
posed of patients’ 1) demographic data, 2) administered
contrast agents, 3) allergic history, 4) medical history, and
5) laboratory test results. If patients underwent more than
one CT scan during the study period, only the most recent
data were included.
Demographic data included gender and age. Data on
contrast agents included type of the agent, contrast agent
concentration, and total contrast agent dose [17]. Allergic
history included any history of antibiotics, or any other
drug [10,18]. Medical history included atopic dermatitis,
urticaria, asthma, hypertension, diabetes, and dyslipidemia
[10,16] (Table 1). Laboratory test results were collected by
routine blood draw.
Adverse reactions to contrast agents are defined based on
the previous study [19]. Acute reactions which occurTable 1 Check list of baseline parameters
Gender Allergic History






Atopic dermatitis, asthma, urticaria, diabetes,
hypertension, dyslipidemia
Laboratory values
BUN*, Cre†, Na, K, Cl, T-bil‡, AST§, ALT** ,
LDH††, Glu‡‡, HgbA1c§§, WBC***, Hgb†††,
Plt‡‡‡,
BUN*: Blood urea nitrogen. Cre†: Creatinine. T-bil‡ Total-bilirubin. AST§:
Aspartate aminotransferase. ALT**: Alanine aminotransferase. LDH††: Lactate
dehydrogenase. Glu‡‡: Glucose. HgbA1c§§: Hemoglobin A1c. WBC***: White
Blood Cell. Hgb†††: Hemoglobin. Plt‡‡‡: Platelet.immediately during the injection of the contrast agents up
to one hour afterwards, were observed and documented by
a trained radiologist or nurse in charge of the examination
for several hours after imaging. Non-acute (delayed) reac-
tions occur more than one hour after the injection of the
contrast agent. After discharge, patients were followed up
at home for any reactions occurring within 24 hours of
contrast administration by self reporting. Albeit infrequent,
severe adverse reactions involving prolonged hypertension,
angina, ventricular fibrillation, based on the previous study
[20]. We analyzed all kinds of these adverse reactions.Statistical analysis
Descriptive statistics were employed to characterize sub-
jects’ baseline data. In order to facilitate the use of the
prediction rule in the clinical setting, continuous values
were categorized into groups. Following the method-
ology of previous studies, laboratory test results and
continuous values were dichotomized based on average
values [21]. We randomly divided approximately 2/3 of
patients into derivation group and others into a valid-
ation group. Randomization was performed by computer
based random number table.
Univariate analysis was performed to investigate the
relationship between collected data and adverse reac-
tions. In order to select final prognostic predictors, all
candidate predictors for which p-value was <0.2 in uni-
variate analysis, as well as other clinically important vari-
ables, were included in a forward stepwise logistic
regression model, with a subsequent p-value of 0.05
required for inclusion in the final model. Scores for each
predictor were obtained based on the beta value from
the final prediction model; total scores were calculated
respectively. We decided the variable which had mini-
mum β coefficient as a predict point 1 and the predict
points of other variables based on the ratio of β coeffi-
cient of each variable to minimum variable. In order to
compare the incidence of adverse reactions, patients
were divided into groups according to total score. A re-
ceiver operator characteristic (ROC) curve was then
drawn, and the area under the curve (AUC) and inci-
dence of adverse reaction at each point were obtained.
For validation, the same process was performed in the
derivation group. In addition, we calculated sensitivity,
specificity, positive and negative likelihood ratio at sev-
eral scoring cut-off points.
All analyses were conducted using SPSS software package
version 15.0 (IBM, Tokyo, Japan), except 95% confidence
intervals (CI) which were based on an exact binominal [22]
using Stata version 10 (STATA Corp., College Station,
USA). Ethical approval was obtained from the Research
Ethics Committee of St. Luke’s International Hospital,
Tokyo, Japan.
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CT imaging with contrast agents was performed on
36,472 patients between April 1, 2004 and March 31,
2011. Of these, 20,000 patients were assigned to the deriv-
ation group and 16,472 patients to the validation group.
Table 2 shows patients characteristics in both groups.
There were 409 (2.0%; 95% CI, 1.9-2.3) adverse reactions







Acute adverse reaction, n (%) 409 (2.0) 347 (2.1)
Severe reaction, n (%) 9 (0.1) 14 (0.1)
Male, n (%) 10396 (52.0) 8506 (51.6)
Age, mean (SD), year 58.3 (16.6) 58.3 (16.7)
Contrast agent concentration, mean
(SD),%
65.2 (6.4) 65.2 (6.2)
Total contrast agent dose, mean (SD), g 62.5 (10.4) 62.5 (9.1)
Allergic History
For radio contrast, n (%) 464 (2.3) 389 (2.4)
For antibiotics, n (%) 589 (2.9) 498 (3.0)
For any drugs, n (%) 1544 (7.7) 1354 (8.2)
Medical history
Atopic dermatitis, n (%) 256 (1.3) 212 (1.3)
Asthma, n (%) 148 (0.7) 128 (0.8)
Urticaria, n (%) 1159 (5.8) 859 (5.5)
Diabetes, n (%) 3929 (19.6) 3209 (19.5)
Hypertension, n (%) 5712 (28.6) 4749 (28.7)
Dyslipidemia, n (%) 3242 (16.2) 2730 (16.6)
Laboratory values
BUN*, mean (SD), mg/dl 15.5 (8.4) 15.5 (8.5)
Cre† , mean (SD), mg/dl 0.9 (0.9) 0.8 (0.8)
Na, mean (SD), mEq/L 140.0 (3.3) 140.0 (3.3)
K, mean (SD), mEq/L 4.1 (0.5) 4.1 (0.5)
Cl, mean (SD), mEq/L 104.9 (3.7) 104.9 (3.7)
T-bil‡, mean (SD), mg/dl 0.8 (1.0) 0.8 (1.3)
AST§, mean (SD), IU/L 40.7 (264.6) 39.4 (140.0)
ALT**, mean (SD), IU/L 35.2 (137.2) 34.5 (109.1)
LDH††, mean (SD), IU/L 233.2 (475.1) 232.4 (337.7)
Glu‡‡, mean (SD), mg/dl 120.9 (47.6) 120.5 (48.2)
HgbA1c§§, mean (SD),% 5.6 (1.2) 5.6 (1.2)
WBC***, mean (SD), ×103 /μl 7.3 (5.0) 7.3 (4.7)
Hgb†††, mean (SD), g/dl 12.9 (2.1) 12.9 (2.1)
Plt‡‡‡, mead (SD), ×103 /μl 235.5 (86.4) 235.5 (84.2)
BUN*: Blood urea nitrogen. Cre†: Creatinine. T-bil‡ Total-bilirubin. AST§:
Aspartate aminotransferase. ALT**: Alanine aminotransferase. LDH††: Lactate
dehydrogenase. Glu‡‡: Glucose. HgbA1c§§: Hemoglobin A1c. WBC***: White
Blood Cell. Hgb†††: Hemoglobin. Plt‡‡‡: Platelet.Severe reactions, such as shock, hypotension, desaturation,
and airway obstruction were observed in 9 cases (0.0005%;
95% CI, 0.0002-0.0009) in the derivation group and 14
(0.0008%; 95% CI, 0.0005-0.0014) in the validation group.
The most frequent reaction was nausea and/or vomiting
at 241 occurrences (31.8%; 95% CI, 28.6-35.3), followed by
rash at 189 (25%; 95% CI, 21.9-28.2), and coughing or
sneezing at 60 (7.9%; 95% CI, 6.1-10.1). Several patients
had multiple symptoms simultaneously. All patients were
prescribed non-ionic, low-osmolar contrast agents (iopa-
midol, iohexol, ioversol or iomeprol).
Logistic regression analysis was constructed with all of
the candidate predictors which were significant on univari-
ate analysis. Adverse reaction history for contrast agents
(odds ratio [OR], 7.1; 95% CI, 5.2-9.7), urticaria (OR 2.7;
95% CI, 2.0-3.6), allergic history to drugs other than con-
trast agents (OR 1.9; 95% CI, 1.5-2.6), contrast agent
concentration >70% (OR 1.9; 95% CI, 1.5-2.4), age <50
years (OR 1.8; 95% CI, 1.4-2.2), and total contrast agent
dose > 65 g (OR 1.4; 95% CI, 1.1-1.7) met inclusion criteria.
Table 3 shows the final model of prognostic predictors. It
was based on assigning predict points to each patient and
determining the sum. A prediction model with a maximum
score of 17 points was derived. Total scores of 0–2 point,
3–5 points, 6–8 points, and ≥9 points, were associated
with adverse reaction rates of 1.4% (95% CI, 1.2-1.5), 3.5%
(95% CI, 2.9-4.2), 9.1% (95% CI, 6.5-12.2), and 14.6%
(95% CI, 10.1-20.0), respectively (Figure 1). We calculated
the sum of scores for each patient and drew an ROC curve
(Figure 2). The AUC of this prediction rule was 0.70
(95% CI, 0.67-0.73). For severe adverse reaction to contrast
agent, we were not able to evaluate prediction model, be-
cause the incidence was quite low.
We conducted validation of the derived prediction
model with 16,472 subjects in the validation group.
Adverse reaction rates were 1.5% (95% CI, 1.3-1.7), 3.6%










1.96 1.64 - 2.27 7.07 < 0.001 7
Urticaria 0.98 0.70 - 1.27 2.67 < 0.001 3
Allergic history for
any drugs




0.63 0.38 - 0.88 1.88 < 0.001 2
Age under 50
years




0.31 0.07 - 0.55 1.36 0.011 1
Figure 1 Adverse reaction for radio contrast on the Logistic Regression Model.
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(Figure 1). ROC curve was also drown with the valid-
ation group and the AUC was 0.67 (95% CI; 0.64-0.70)
(Figure 2) and was similar to data from the derivation
group. Sensitivity, specificity, and positive and negative
likelihood ratios at each cut-off point were calculated
and are shown in Table 4.Figure 2 ROC curve of Radio contrast adverse reaction prediction scoDiscussion
In this study, we propose a prediction model for estimating
the incidence of all kinds of adverse reaction in patients
undergoing contrast enhanced CT imaging. The six predic-
tors identified by multivariate logistic regression analysis
were an adverse reaction history to contrast agents, urti-
caria, allergic history to any other drug, contrast agentres.
Table 4 Sensitivity, specificity, positive and negative












1 79.6 59.3 1.96 0.34
3 45.5 79.9 2.26 0.68
6 17.1 97.1 5.9 0.85
9 7.6 99.1 8.4 0.93
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administered iodine dose. AUC demonstrated acceptable
accuracy (AUC= 0.70, p < 0.001, 95% CI: 0.67-0.73).
This is the first study to propose a model to quantita-
tively estimate risk of adverse reactions to contrast
agents. Predictors in our model are consistent with pre-
viously reported risk factors, such as a history of adverse
reaction to contrast agents or allergy to other drugs
[23,24]. Atopic individuals, such as those with asthma,
dermatitis, and urticaria, have also been considered to
be at higher risk for adverse events after contrast agents
administration [10]. After quantitative analysis, urticaria
appears to be the most significant risk factor based on
odds ratio. In addition, while we know of no previous
study evaluating patient’s age in association with adverse
reactions, one previous study demonstrated that older
patients may have stronger reactions to histamine [25].
Finally, the dose of administered iodine has been shown
to be associated with iodine allergy [26] ,while chemo-
toxic reactions are known to be dependent on dose and
infusion rate [13].
Several previously reported risk factors, including
asthma and type of contrast agents, were also consid-
ered in our study, but were consequently not included
among our final predictors. Previous literature sug-
gested that well-controlled asthma patients may not
continue to be at risk for contrast agents reactions al-
though un-controlled patients are at risk [16]. In our
study, in order to facilitate clinical utility of the model,
we did not differentiate between well-controlled and
uncontrolled asthma patients. In addition, in Japan,
patients with a history of asthma are often considered
poor candidates for receiving contrast, which may be
avoided at the discretion of the treating radiologist at
our institution. Due to treatment differences and the
potential for a priori exclusion, asthma might have
escaped inclusion as a predictor in our study. Similarly,
osmolarity of contrast agents has been shown to be
associated with adverse reactions [27]. In our study, all
patients received low osmolar contrast agents, of which
there was little difference in contrast agent concentra-
tion between the different types, precluding evaluation
of higher osmolar agents.There were some limitations in our study. First, our
prediction model was not precise to predict adverse re-
action [28]. However, at a scoring cut-off of 6 and 9, the
specificity was 97.1% and 99.1%, respectively. These high
specificities are useful in predicting which individuals
may be at high-risk of having an adverse reaction and
scoring can be done pre-imaging, thus facilitating appro-
priate observation periods and/or pre-procedure prophy-
lactic therapy with steroids or antihistamines [27,29].
Second, our study was conducted only in one hospital,
at which the majority of patients were Japanese.
Although both large in scale and validated, prospective
studies at multiple centers and with heterogeneous
populations are needed in the future to further refine
the model.Conclusion
We propose a validated prediction model for adverse
reactions to contrast agents consisting of six predictors—
allergic history to contrast agents, urticaria, history of pre-
vious allergy to drugs other than contrast agents, contrast
agent concentration > 70%, age <50 years old, and a total
contrast agent dose >65 g. Using the scoring model, this
set of predictors is easy to calculate in the clinical setting
and may facilitate appropriate referrals for enhanced im-
aging by outpatient physicians, as well as management of
high-risk patients by radiologists and inpatient physicians.Abbreviations
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